ArticleBioprocess and biosystems engineering2025
Prevalence and effective treatment of drug-resistant Pseudomonas aeruginosa biofilm using flavonoid naringin.
Article in Bioprocess and biosystems engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Functional Peptides: Comparing Synthetic and Sequence-Engineered Antibiofilm Pharmaceutics.Pharmaceutics · 2026Review
- Possible applicability of flavonoid hesperetin for the treatment of dental biofilm-formingJournal of oral biology and craniofacial researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa infections and biofilms are difficult to treat due to their remarkable ability of antibiotic resistance. Consequently, the incidence of drug-resistant P. aeruginosa infection cases is steadily increasing in hospitals worldwide. Herein, the frequency of drug-resistant P. aeruginosa wound infection cases among hospitalized patients is examined. In addition, suitable natural components with potent antibacterial activity against the drug-resistant P. aeruginosa strains are screened. Among 27 specimens, three P. aeruginosa strains (including carbapenem and multidrug-resistant) are isolated. The antibacterial efficacy of natural components, such as curcumin, naringin, quercetin, tannic acid, and rutin, is evaluated against the isolated drug-resistant P. aeruginosa strains. Comparatively, naringin showed great antibacterial potential against drug-resistant P. aeruginosa strains. The zone of inhibition is found between 13 and 16 mm for naringin (20 mM) against P. aeruginosa strains; while, the minimum inhibitory concentration is found between 10 and 14 mM. A complete eradication of bacterial cells in P. aeruginosa mature biofilm is achieved by naringin at 28 mM within 24 h. Naringin interacts with the most important amino acids found in the MexR and RlpA, which confirms its role in the targeted treatment of drug-resistant P. aeruginosa. Remarkably, naringin is found to be hemocompatible up to 30 mM. Overall, this study suggests that naringin might be an outstanding biocompatible natural component to effectively treat multidrug-resistant P. aeruginosa infections and biofilms.
Indexed as
Identifiers
40952478What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.